Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 13, 2026
TickeronGET DAILY SIGNALS
LNKS vs TCRT: Contrasting Two Micro-Cap Stocks in Manufacturing and Biotech

LNKS vs TCRT: Contrasting Two Micro-Cap Stocks in Manufacturing and Biotech

Key Takeaways

  • LNKS (Linkers Industries) is a Malaysia-based manufacturer of wire and cable harnesses, while TCRT (Alaunos Therapeutics) is a clinical-stage biotechnology company.
  • The two companies operate in unrelated sectors—industrial manufacturing versus oncology and cardiopulmonary drug development—making this a study in contrasting risk profiles.
  • LNKS recently executed a 1-for-250 reverse share split and raised roughly $16 million in gross proceeds through the exercise of Series B warrants.
  • TCRT completed its acquisition of Velaris Therapeutics and secured new financing, but reports minimal cash, near-zero revenue, and ongoing net losses.
  • Both are small-cap, thinly traded securities with histories of share consolidation and elevated price volatility.

Introduction

Comparing two micro-cap stocks from entirely different industries can reveal how market positioning, capital structure, and catalysts shape relative performance. LNKS, a Malaysian wire-harness manufacturer, and TCRT, a clinical-stage biopharmaceutical developer, present sharply different business models and risk dynamics. This stock comparison is relevant to traders evaluating momentum and volatility, as well as investors assessing fundamental quality, financing needs, and long-term viability. Both names have recently undergone corporate actions that influenced their share prices, making a side-by-side review of their recent market behavior and positioning timely. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.

LNKS Overview and Recent Performance

Linkers Industries Limited is a manufacturer and supplier of customized wire and cable harnesses with more than 20 years of experience and operations in Malaysia. The company serves global brand-name manufacturers and original equipment manufacturers (OEMs) across home appliances, industrial products, and automotive applications, primarily in the Asia-Pacific region.

In recent market activity, LNKS has been shaped by corporate capital events rather than purely operational news. The company announced a 1-for-250 reverse share split of its Class A and Class B ordinary shares, a consolidation intended to address its low share price. Around the same period, it disclosed that all Series B warrants tied to its March 2026 public offering had been fully exercised, generating approximately $16 million in gross proceeds. These actions have contributed to wide daily percentage swings, and the stock has traded in a notably broad range over the past year. The underlying business remains a niche industrial supplier, with its market valuation influenced heavily by limited float and capital-raising activity.

TCRT Overview and Recent Performance

Alaunos Therapeutics, Inc. is a biotechnology company historically focused on adoptive T-cell receptor (TCR-T) cell therapies for solid tumors, with additional preclinical programs in obesity. More recently, the company has pivoted toward specialty biopharma through the acquisition of Velaris Therapeutics, a private developer of therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, backed by institutional healthcare investors.

Recent performance for TCRT has reflected both restructuring and persistent financial pressure. The stock is down roughly 70% over the trailing 52 weeks and trades well below its 50-day and 200-day moving averages. The company reports very limited cash (about $124,000), essentially no meaningful revenue, and trailing twelve-month net losses of roughly $4.1 million. These figures, combined with a market capitalization of only a few million dollars and a prior 1-for-10 reverse split, highlight the dilution and funding risks that characterize the name. Sentiment has been sensitive to financing announcements, listing-compliance concerns, and pipeline updates. From what I see, the financing history adds another layer to watch closely.

Head-to-Head Comparison

The most fundamental contrast between these two stocks is their business model. LNKS operates a tangible, revenue-generating manufacturing business with established OEM relationships, whereas TCRT is a development-stage biotech whose value depends largely on future clinical milestones and continued capital infusions.

On growth drivers, LNKS's trajectory is tied to industrial and automotive demand in Asia-Pacific plus its ability to deploy newly raised capital, while TCRT's outlook rests on its acquired Velaris pipeline and the successful advancement of its programs. On risk factors, LNKS faces a concentrated customer base, thin liquidity, and a heavily consolidated share structure; TCRT confronts clinical, regulatory, and financing risk, underscored by its minimal cash balance and recurring losses.

In terms of sector exposure, LNKS offers cyclical manufacturing exposure, whereas TCRT provides speculative, event-driven healthcare exposure. Recent momentum has been headline-driven for both names—corporate actions for LNKS and restructuring announcements for TCRT—but neither has yet demonstrated durable, fundamental-backed trend consistency. I’m watching this closely as the volatility patterns evolve.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability, and the quality of catalysts, Tickeron's AI would likely lean toward LNKS over TCRT in the current environment. LNKS's operational revenue base and recent capital infusion provide a comparatively more stable footing, whereas TCRT's minimal cash, near-zero revenue, and heavy reliance on dilution present a less favorable risk profile. That said, this is a probabilistic assessment rather than a definitive prediction: TCRT's biotech catalysts can produce sharp moves, and both stocks carry elevated volatility. Any relative advantage would depend on sustained trend signals and improving fundamentals rather than short-term price swings.

Using AI Trading Bots in My Research

Tickeron operates hundreds of AI Trading Bots that actively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of target securities. In my own process, I find the curated selection helpful for spotting approaches that align with shifting market conditions. Exploring these tools has become a regular part of how I evaluate signals across volatile names like these.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCRT, LNKS

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


TCRT in +7.50% Uptrend, rising for three consecutive days on November 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer treatment company

Industry Biotechnology

Industry
Biotechnology
Address
501 East Las Olas Boulevard
Phone
+1 346 355-4099
Employees
1
Web
https://www.alaunos.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.